PFE Jan 2024 33.000 call
| Previous Close | 8.86 |
| Open | 8.86 |
| Bid | 8.70 |
| Ask | 8.85 |
| Strike | 33.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 8.86 - 8.86 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 614 |
- Reuters
UPDATE 1-US declines to force lower price on cancer drug Xtandi
The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, a federal agency said on Tuesday. The Union for Affordable Cancer Treatment, a patient group, had first filed a petition calling on the National Institutes of Health (NIH) to use its authority to lower the drug's price in March 2016. The NIH said in a letter made public on Tuesday that its analyses in response to the petition found that the prostate cancer treatment was widely available.
- Motley Fool
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally.
- Reuters
US declines to force lower price on cancer drug Xtandi
The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, a federal agency said on Tuesday. The Union for Affordable Cancer Treatment, a patient group, had first filed a petition calling on the National Institutes of Health (NIH) to use its authority to lower the drug's price in March 2016. The NIH said in a letter made public on Tuesday that its analyses in response to the petition found that the prostate cancer treatment was widely available.
